About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Pparg
peroxisome proliferator activated receptor gamma
MGI:97747
246 phenotypes from 26 alleles in 29 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Ppargm1Btlr/Ppargm1Btlr
C57BL/6J-Ppargm1Btlr
decreased body weight J:265098
Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Ppargtm1.1Auw
abnormal bone structure J:144344
abnormal cell differentiation J:144344
abnormal circadian temperature homeostasis J:144344
decreased body mass index J:144344
decreased body weight J:144344
decreased circulating cholesterol level J:144344
decreased circulating triglyceride level J:144344
decreased total fat pad weight J:144344
extended life span J:144344
normal homeostasis/metabolism phenotype J:144344
hyperactivity J:144344
improved glucose tolerance J:144344
increased adipocyte glucose uptake J:144344
increased fluid intake J:144344
increased insulin sensitivity J:144344
Ppargtm1.1Auw/Ppargtm1.1Auw
either: 129 or C57BL/6J or (involves: 129 * C57BL/6J)
normal adipose tissue phenotype J:86705
Ppargtm1.1Gonz/Ppargtm1.1Gonz
involves: 129X1/SvJ * FVB
cardiac hypertrophy J:112034
decreased heart rate J:112034
enlarged myocardial fiber J:112034
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
abnormal kidney morphology J:168799
abnormal macrophage activation involved in immune response J:168799
abnormal nephron morphology J:168799
abnormal peritoneal macrophage morphology J:168799
abnormal podocyte foot process morphology J:168799
abnormal renal glomerulus morphology J:168799
albuminuria J:168799
enlarged kidney J:168799
expanded mesangial matrix J:168799
fused podocyte foot processes J:168799
glomerulonephritis J:168799
impaired macrophage phagocytosis J:168799
increased anti-double stranded DNA antibody level J:168799
increased anti-nuclear antigen antibody level J:168799
increased anti-single stranded DNA antibody level J:168799
increased autoantibody level J:168799
increased circulating creatine level J:168799
increased IgG level J:168799
increased IgM level J:168799
increased kidney weight J:168799
increased renal glomerulus apoptosis J:168799
increased renal glomerulus basement membrane thickness J:168799
increased urine protein level J:168799
mesangial cell hyperplasia J:168799
renal glomerulus hypertrophy J:168799
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Aqp2-cre)1Dek/0
involves: 129X1/SvJ * C57BL/6 * SJL
abnormal blood volume J:99873
abnormal body weight J:99873
abnormal circulating aldosterone level J:99873
abnormal hematocrit J:99873
abnormal physiological response to xenobiotic J:99873
abnormal renal sodium ion transport J:99873
abnormal urine sodium level J:99873
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Ins2-cre)25Mgn/0
involves: 129 * C57 * FVB
pancreatic islet hyperplasia J:89959
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Mx1-cre)1Cgn/?
involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N
abnormal macrophage physiology J:75777
Ppargtm1.1Mgn/Ppargtm1.1Mgn
involves: 129S6/SvEvTac * C57BL/6J
no abnormal phenotype detected J:75120
Ppargtm1.1Mtz/Ppargtm1.1Mtz
involves: C57BL/6
abnormal placenta development J:89238
embryonic lethality during organogenesis, complete penetrance J:89238
Ppargtm1.1Unc/Pparg+
involves: 129S6/SvEvTac * C57BL/6J
decreased systemic arterial blood pressure J:154767
Ppargtm1.1Unc/Ppargtm1.1Unc
involves: 129S6/SvEvTac * C57BL/6J
decreased systemic arterial blood pressure J:154767
normal homeostasis/metabolism phenotype J:154767
impaired glucose tolerance J:154767
Ppargtm1.2Auw/Ppargtm1.2Auw
B6.Cg-Ppargtm1.2Auw
premature death J:161746
Ppargtm1.2Mgn/Ppargtm1.2Mgn
involves: 129S6/SvEvTac * C57BL/6J
prenatal lethality, complete penetrance J:75120
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
abnormal adipose tissue physiology J:89238
abnormal brown fat cell morphology J:89238
abnormal white fat cell morphology J:89238
decreased brown adipose tissue amount J:89238
decreased epididymal fat pad weight J:89238
decreased percent body fat/body weight J:89238
increased brown fat cell lipid droplet size J:89238
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(Krt10-cre/ERT2)1Pcn/0
involves: C57BL/6 * SJL
abnormal keratinocyte morphology J:109090
abnormal skin morphology J:109090
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(KRT14-cre)1Ipc/0
involves: C57BL/6 * SJL
no abnormal phenotype detected J:109090
Ppargtm1Auw/Ppargtm1Auw
either: 129 or C57BL/6J or (involves: 129 * C57BL/6J)
abnormal brown adipose tissue morphology J:86705
abnormal circulating alanine transaminase level J:86705
abnormal glucose homeostasis J:86705
decreased body temperature J:86705
decreased body weight J:86705
decreased brown adipose tissue mass J:86705
decreased white adipose tissue mass J:86705
enlarged liver J:86705
hepatic steatosis J:86705
hyperlipidemia J:86705
impaired glucose tolerance J:86705
increased circulating aspartate transaminase level J:86705
increased circulating free fatty acid level J:86705
increased circulating triglyceride level J:86705
increased liver triglyceride level J:86705
insulin resistance J:86705
lipodystrophy J:86705
postnatal growth retardation J:86705
postnatal lethality, incomplete penetrance J:86705
Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
abnormal adipose tissue distribution J:116568
abnormal fat cell differentiation J:116568
abnormal lipid homeostasis J:116568
abnormal triglyceride level J:116568
decreased circulating adiponectin level J:116568
normal growth/size/body region phenotype J:116568
hepatic steatosis J:116568
normal homeostasis/metabolism phenotype J:116568
increased circulating triglyceride level J:116568
increased liver weight J:116568
Ppargtm1Avp/Ppargtm1Avp
involves: 129S2/SvPas * C57BL/6
preweaning lethality, complete penetrance J:116568
Ppargtm1b(KOMP)Wtsi/Pparg+
C57BL/6N-Ppargtm1b(KOMP)Wtsi/H
abnormal gait J:211773
Ppargtm1b(KOMP)Wtsi/Ppargtm1b(KOMP)Wtsi
C57BL/6N-Ppargtm1b(KOMP)Wtsi/H
preweaning lethality, complete penetrance J:211773
Ppargtm1Gonz/Ppargtm1Gonz
Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB
abnormal mammary gland growth during pregnancy J:76553
decreased litter size J:76553
female infertility J:76553
reduced female fertility J:76553
Ppargtm1Gonz/Ppargtm1Gonz
Tg(MMTV-cre)4Mam/?
involves: 129X1/SvJ * FVB
normal reproductive system phenotype J:76553
Ppargtm1Gonz/Ppargtm1Gonz
Tg(Wap-cre)11738Mam/?
involves: 129X1/SvJ * C57BL/6 * SJL
normal reproductive system phenotype J:76553
Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
abnormal glucose homeostasis J:135904
decreased circulating free fatty acid level J:135904
decreased circulating leptin level J:135904
decreased circulating triglyceride level J:135904
decreased fat cell size J:135904
improved glucose tolerance J:135904
increased circulating adiponectin level J:135904
increased insulin sensitivity J:135904
Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
abnormal brown fat cell morphology J:98786
abnormal epididymal fat pad morphology J:98786
decreased body fat mass J:98786
decreased body weight J:98786
decreased circulating adiponectin level J:98786
decreased muscle cell glucose uptake J:98786
decreased white fat cell size J:98786
hepatic steatosis J:98786
hypertension J:98786
increased circulating free fatty acid level J:98786
increased circulating insulin level J:98786
increased liver triglyceride level J:98786
insulin resistance J:98786
lipodystrophy J:98786
Ppargtm1Lja/Ppargtm1Lja
involves: 129S1/Sv * 129X1/SvJ
decreased embryo size J:98786
embryonic lethality, complete penetrance J:98786
Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
abnormal adipose tissue distribution J:91362
abnormal endocrine pancreas morphology J:91362
abnormal fat cell morphology J:91362
abnormal gonadal fat pad morphology J:91362
abnormal inguinal fat pad morphology J:91362
hypertension J:91362
improved glucose tolerance J:91362
Ppargtm1Mae/Ppargtm1Mae
involves: 129S6/SvEvTac * C57BL/6
prenatal lethality, complete penetrance J:91362
Ppargtm1Rev/Pparg+
involves: 129S4/SvJae * C57BL/6J
abnormal glucose homeostasis J:60354
increased insulin sensitivity J:60354
Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
abnormal chorionic plate morphology J:58223
abnormal fetal cardiomyocyte morphology J:58223
abnormal myocardial fiber morphology J:58223
abnormal myocardial trabeculae morphology J:58223
abnormal placenta hemotrichorial membrane morphology J:58223
abnormal placenta labyrinth morphology J:58223
abnormal placenta morphology J:58223
abnormal placental labyrinth vasculature morphology J:58223
abnormal trophoblast giant cell morphology J:58223
abnormal trophoblast layer morphology J:58223
embryonic lethality during organogenesis, complete penetrance J:58223
thin interventricular septum J:58223
thin myocardium J:58223
thin ventricle myocardium compact layer J:58223
thin ventricular wall J:58223
Ppargtm1Rev/Ppargtm2Mae
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J
increased systemic arterial blood pressure J:154767
Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
abnormal bone marrow development J:89250
abnormal bone marrow morphology J:89250
abnormal bone ossification J:89250
abnormal cell differentiation J:58222
abnormal fat cell morphology J:58222, J:89250
abnormal osteoblast differentiation J:89250
abnormal response to injury J:103209
abnormal retinal vasculature morphology J:116269
decreased brown adipose tissue amount J:58222
decreased circulating insulin level J:58222
decreased food intake J:58222
decreased susceptibility to diet-induced obesity J:58222
decreased susceptibility to hepatic steatosis J:58222
decreased total body fat amount J:58222
increased body temperature J:58222
increased circulating leptin level J:58222
increased incidence of tumors by chemical induction J:98823
increased insulin sensitivity J:58222
increased osteoblast cell number J:89250
increased sensitivity to xenobiotic induced morbidity/mortality J:98823
increased trabecular bone mass J:89250
leukostasis J:116269
normal skeleton phenotype J:89250
Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR
abnormal B cell physiology J:58222
abnormal humoral immune response J:58222
abnormal response to injury J:68579
normal immune system phenotype J:58222
increased B cell proliferation J:58222
increased IgG level J:58222
increased IgM level J:58222
increased interferon-gamma secretion J:58222
increased interleukin-2 secretion J:58222
increased susceptibility to induced arthritis J:58222
Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA
abnormal cell differentiation J:58222, J:89250
abnormal heart development J:58222
abnormal placenta labyrinth morphology J:58222
abnormal placental labyrinth vasculature morphology J:58222
embryonic growth retardation J:58222
embryonic lethality during organogenesis, complete penetrance J:58222
placental labyrinth hypoplasia J:58222
thin myocardium J:58222
Ppargtm1Uls/Pparg+
involves: 129S2/SvPas * C57BL/6
decreased total body fat amount J:92826
postnatal growth retardation J:92826
Ppargtm1Uls/Ppargtm1Uls
involves: 129S2/SvPas * C57BL/6
prenatal lethality, complete penetrance J:92826
Ppargtm1Wwah/Pparg+
Not Specified
normal immune system phenotype J:71272
Ppargtm1Wwah/Ppargtm1Wwah
Not Specified
prenatal lethality J:71272
Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
abnormal brown adipose tissue morphology J:91479
abnormal white adipose tissue morphology J:91479
abnormal white adipose tissue physiology J:91479
decreased body weight J:91479
decreased brown fat cell lipid droplet size J:91479
decreased brown fat lipid droplet number J:91479
decreased circulating adiponectin level J:91479
decreased circulating leptin level J:91479
decreased gonadal fat pad weight J:91479
decreased inguinal fat pad weight J:91479
decreased retroperitoneal fat pad weight J:91479
decreased white adipose tissue amount J:91479
decreased white fat cell number J:91479
decreased white fat cell size J:91479
insulin resistance J:91479
normal liver/biliary system phenotype J:91479
Ppargtm2(tTA)Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
abnormal brown adipose tissue morphology J:125992
abnormal hepatocyte morphology J:125992
abnormal white adipose tissue morphology J:125992
abnormal white fat cell morphology J:125992
abnormal white fat cell size J:125992
absent subcutaneous adipose tissue J:125992
normal adipose tissue phenotype J:125992
decreased gonadal fat pad weight J:125992
enlarged liver J:125992
normal homeostasis/metabolism phenotype J:125992
hyperglycemia J:125992
impaired glucose tolerance J:125992
increased brown fat cell size J:125992
increased circulating cholesterol level J:125992
increased circulating free fatty acid level J:125992
increased circulating insulin level J:125992
increased circulating triglyceride level J:125992
increased interscapular fat pad weight J:125992
insulin resistance J:125992
pancreas hyperplasia J:125992
pancreatic islet hyperplasia J:125992
reduced fertility J:125992
Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
abnormal pancreatic islet morphology J:121534
decreased circulating adiponectin level J:121534
Ppargtm2Avp/Ppargtm2Avp
Not Specified
abnormal adipose tissue distribution J:121693
abnormal glucose homeostasis J:121693
abnormal white adipose tissue physiology J:121693
decreased circulating adiponectin level J:121693
decreased total body fat amount J:121693
impaired glucose tolerance J:121693
increased circulating glucose level J:121693
increased circulating leptin level J:121693
increased fat cell size J:121693
normal reproductive system phenotype J:121693
Ppargtm2Rev/Ppargtm2Rev
Tg(Cd4-cre)1Cwi/?
involves: 129S4/SvJae * C57BL/6 * DBA/2
abnormal T-helper 17 cell differentiation J:153358
increased susceptibility to experimental autoimmune encephalomyelitis J:153358
Ppargtm2Rev/Ppargtm2Rev
Tg(Fabp4-cre)1Rev/0
involves: 129S4/SvJae * C57BL/6
abnormal brown adipose tissue morphology J:88210
abnormal brown fat cell size J:88210
abnormal white adipose tissue amount J:88210
decreased brown adipose tissue amount J:88210
decreased brown fat cell number J:88210
decreased interscapular fat pad weight J:88210
enlarged liver J:88210
hepatic steatosis J:88210
increased brown fat cell size J:88210
increased circulating insulin level J:88210
increased white fat cell size J:88210
insulin resistance J:88210
slow postnatal weight gain J:88210
Ppargtm2Rev/Ppargtm2Rev
Tg(Krt1-15-cre/PGR)22Cot/?
involves: 129S4/SvJae * C57BL/6 * SJL
abnormal coat appearance J:150977
abnormal hair follicle morphology J:150977
abnormal hair follicle ostium morphology J:150977
abnormal skin adnexa morphology J:150977
abnormal skin appearance J:150977
abnormal skin morphology J:150977
abnormal skin sebaceous gland morphology J:150977
excessive scratching J:150977
flaky skin J:150977
hyperkeratosis J:150977
matted coat J:150977
progressive hair loss J:150977
reddish skin J:150977
sebaceous gland atrophy J:150977
skin fibrosis J:150977
skin inflammation J:150977
Ppargtm2Rev/Ppargtm2Rev
Tg(Lhb-cre)1Sac/?
involves: 129S4/SvJae * C57BL/6 * SJL
abnormal diestrus J:170272
decreased circulating follicle stimulating hormone level J:170272
decreased litter size J:170272
increased luteinizing hormone level J:170272
normal reproductive system phenotype J:170272
Ppargtm2Rev/Ppargtm2Rev
Tg(Tagln-cre)1Her/?
involves: 129S4/SvJae * C57BL/6 * SJL
abnormal pulmonary artery morphology J:136168
heart right ventricle hypertrophy J:136168
increased right ventricle systolic pressure J:136168
Ppargtm2Rev/Ppargtm2Rev
Tg(Tek-cre)1Ywa/?
involves: 129S4/SvJae * C57BL/6 * SJL
abnormal bone marrow cavity morphology J:130475
abnormal bone marrow cell morphology/development J:130475
abnormal bone structure J:130475
abnormal bone trabecula morphology J:130475, J:160910
abnormal hair cycle J:123403
abnormal hair cycle anagen phase J:123403
abnormal hair follicle morphology J:123403
abnormal hair shedding J:123403
abnormal mammary gland alveolus morphology J:123403
abnormal osteoclast differentiation J:160910
abnormal osteoclast morphology J:130475
abnormal pulmonary artery morphology J:155909
abnormal skin adnexa morphology J:123403
abnormal spleen morphology J:130475
abnormal splenocyte morphology J:130475
abnormal trabecular bone morphology J:130475
decreased bone marrow cell number J:130475
decreased osteoclast cell number J:130475
enlarged spleen J:130475
extramedullary hematopoiesis J:130475
heart right ventricle hypertrophy J:155909
normal hematopoietic system phenotype J:130475
increased bone mineral density J:130475
increased bone trabecula number J:130475
increased bone volume J:130475
increased right ventricle systolic pressure J:155909
increased splenocyte number J:130475
increased trabecular bone thickness J:130475
increased trabecular bone volume J:130475
increased triglyceride level J:155909
pale liver J:123403
postnatal growth retardation J:123403
premature hair loss J:123403
skin inflammation J:123403
Ppargtm2Rev/Ppargtm2Rev
Tg(Tek-cre)12Flv/?
B6.Cg-Ppargtm2Rev Tg(Tek-cre)12Flv
abnormal vascular endothelial cell physiology J:154216
abnormal vasodilation J:154216
decreased body weight J:154216
decreased hematocrit J:154216
enlarged spleen J:154216
impaired muscle relaxation J:154216
increased mean systemic arterial blood pressure J:154216
Ppargtm2Rev/Ppargtm2Rev
Tg(Ucp1-cre)1Evdr/0
involves: 129S4/SvJae * FVB
abnormal amino acid metabolism J:278806
abnormal interscapular fat pad morphology J:278806
Ppargtm3(tTA)Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
abnormal brown adipose tissue morphology J:125992
abnormal brown fat cell morphology J:125992
decreased gonadal fat pad weight J:125992
decreased subcutaneous adipose tissue amount J:125992
enlarged liver J:125992
increased brown fat cell size J:125992
increased circulating insulin level J:125992
increased circulating triglyceride level J:125992

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/04/2020
MGI 6.14
The Jackson Laboratory